# EDGAR Filing Document

**Accession Number:** 0001825034
**File Stem:** 0001012975-25-000506
**Filing Date:** 2025-9
**Character Count:** 4806
**Document Hash:** ec54ea3ef0b433748e686e9236d4fdb4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001012975-25-000506.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0001012975-25-000506

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250902

**EFFECTIVENESS DATE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Euclidean Capital LLC
- **CENTRAL INDEX KEY:** 0001825034

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-20777
- **FILM NUMBER:** 251285454

**BUSINESS ADDRESS:**
- **STREET 1:** 160 FIFTH AVE, 9TH FL
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 212-537-0335

**MAIL ADDRESS:**
- **STREET 1:** 160 FIFTH AVE, 9TH FL
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001825034

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Euclidean Capital LLC

**Address:** 160 FIFTH AVE, 9TH FL, NEW YORK, NY 10010

**Telephone number:** 212-537-0310

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-20777

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 54930088UJIT3V1XWZ07

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER            | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                        | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| ALECTOR INC               | 014442107 | 06/11/2025     | To conduct an advisory vote to approve the compensation of our named executive officers                                                                 | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| 23ANDME HOLDING CO        | 90138Q108 | 08/26/2024     | A non-binding, advisory vote on the Fiscal 2024 compensation of our named executive officers ("Say-on-Pay" Vote)                                        | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| PMV PHARMACEUTICALS INC   | 69353Y103 | 06/05/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers                                                           | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| QUALIGEN THERAPEUTICS INC | 74754R202 | 10/25/2024     | To approve on a non-binding, advisory basis, the compensation of our named executive officers.                                                          | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| RAPT THERAPEUTICS INC     | 75382E109 | 05/29/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                           | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |
| RAPT THERAPEUTICS INC     | 75382E109 | 05/29/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |              0 |                0 |  |  |  |  |

## N-PX: Signature Block

**Reporting Person:** Euclidean Capital LLC

**By (Signature):** Joseph Cosmai

**By (Printed Signature):** Joseph Cosmai

**By (Title):** Manager

**Date:** 09/02/2025